ACT-1016-0707
ACT-1016-0707 (Compound 49) is an orally active and selective LPA1 receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases[1].
Product Specifications
CAS Number
2569467-78-1
Product Name Alternative
LPA1 receptor antagonist 2
UNSPSC
12352005
Target
LPL Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/act-1016-0707.html
Purity
98.28
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1(C2=CC=CC=C2C(C)C)CN(S(=O)(N)=O)C1)NC3=C(OC)C=C(Cl)N=C3
Molecular Formula
C19H23ClN4O4S
Molecular Weight
438.93
References & Citations
[1]Lescop C, et al. Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases. J Med Chem. 2024 Feb 22;67 (4) :2397-2424.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![TFE3 Recombinant Rabbit Monoclonal Antibody [JE60-60]](https://cdn.genprice.uk/products/992/68dd1c8a061270361ea80dd7/imageurl/ha721896.webp)
HA721896 100 µL
TFE3 Recombinant Rabbit Monoclonal Antibody [JE60-60]
Sign In for Pricing
View Details 